Welcome to the new Gustave Roussy website

A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.

Press releases

ESMO 2018 - Gustave Roussy presentations

On

Changed on

Villejuif, 19 october 2018

Gustave Roussy presentations at ESMO 2018

This year, the European Society for Medical Oncology (ESMO) will take place in Munich, Germany, from 19 to 23 October. It is Europe’s biggest cancer congress and the number of delegates increases year-on-year. Experts from all over the world visit the congress to share the latest clinical innovations in oncology. Around 20,000 delegates from 130 countries are expected to attend ESMO 2018.

Gustave Roussy will undoubtedly be one of the main stakeholders at this congress and specialists will present results during oral presentations, poster discussions and special symposia/posters. 

Professor Fabrice André’s oral presentation of the results of the SOLAR-1 breast cancer study during the plenary session on Saturday, 20 October, is one of the highlights of the congress.

Renowned for their specialist knowledge, Gustave Roussy's experts will also act as moderators in the verbal sessions, symposia or discussions. Professor Karim Fizazi will officiate during a plenary session oral presentation on prostate cancer on Sunday 21 October and Prof. Alexander Eggermont will be the speaker at a “special symposium” session focussing on therapeutic strategies for melanoma and outlining future plans for adjuvant immunotherapy treatments.

Find out Gustave Roussy presentations


▶ Read the press kit

 

 

 

 

 

 

Press contact

If you are a journalist and have a question, please contact:

Claire Parisel or Léona Pinto
Tel. +33 1 42 11 50 59
Tel. +33 1 42 11 63 59
Mob. +33 6 17 66 00 26
Email

The Media Team cannot respond to patient inquiries.

Last press releases

  • Gold september: two new research programmes launched to tackle childhood cancers

    Two of Gustave Roussy’s four new medical and scientific programmes are dedicated to childhood cancers. The first, DECRIPT, aims to improve understanding of the role played by genetics in the development of certain childhood cancers, as well as second cancers that may occur in adulthood. The second, INSPIRE, will draw on the knowledge and techniques already developed at the Institute to create organoids, with the aim of deciphering the mechanisms underlying metastasis and resistance to treatment.

    Photographie enfant pédiatrie
  • Prof. Fabrice Barlesi reappointed at the head of Gustave Roussy, the leading cancer center in France and Europe

    By order of Ms. Stéphanie Rist, Minister of Health, Families, Autonomy and Persons with Disabilities, dated 27 July 2026, Professor Fabrice Barlesi has been reappointed as Director General of Gustave Roussy, effective 1 August 2026. At the helm of the Institute for five more years, Prof. Barlesi will continue the transformations undertaken during his first term. This renewal reflects the confidence placed in the project led by the institution to accelerate progress in the fight against cancer, foster and support the development of innovations set to change the future of oncology, and strengthen the influence of one of the world's leading cancer centers.

    Fabrice Barlesi
  • Route du Rhum 2026 Jean Le Cam and Christophe Rateau to sail for Gustave Roussy

    For the Route du Rhum - Destination Guadeloupe 2026, Jean Le Cam and Christophe Rateau will sail under the colors of Gustave Roussy, the leading cancer center in France and Europe. Competing respectively in the Vintage and Class40 categories, the two skippers will carry the Institute's mission to the general public, supporting cancer research and raising awareness of prevention, innovation and patient care.

    Jean Le Cam - Christophe Rateau
  • Owkin and Gustave Roussy partner to bring K Pro into real-world clinical practice

    Owkin and Gustave Roussy, Europe's leading cancer center, today announced a partnership to test K Pro directly within the hospital's real-world clinical and research workflows.